Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Spotlight
GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines
Business
Deals
Earnings
Manufacturing
Policy & Regulation
Regulatory Landscape
Drug Pricing
IP & Litigation
Tools & Trackers
What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings
Podcasts
Conference Coverage
Partner Insights
Generics Bulletin Perspectives
Exploring market-shifting topics for the off-patent sector.
View
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Invega Trinza, Pentasa, and Abilify LAI Top Viatris’ First Complex Ambitions
Recent First-Time Restasis Launch Among $600m Of 2022 Product Launches
Mar 03 2022
•
By
Dean Rudge
Viatris is hoping to lead the race in several key launches • Source: Shutterstock
More from Strategy
More from Business
